

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau



B3

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

| | | |
|--|-----------|--|
| (51) International Patent Classification ⁶ : A61K 38/00, C07K 1/00, G01N 33/48, 33/566 | A1 | (11) International Publication Number: WO 99/08695 (43) International Publication Date: 25 February 1999 (25.02.99) |
| (21) International Application Number: PCT/US98/16809 (22) International Filing Date: 13 August 1998 (13.08.98) (30) Priority Data: 60/055,660 14 August 1997 (14.08.97) US (71) Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA [US/US]; 22nd floor, 300 Lakeside Drive, Oakland, CA 94612-3550 (US). (72) Inventors: GLABE, Charles; 20 Curie Court, Irvine, CA 92612 (US). GARZON-RODRIGUEZ, William; 1406 Balo Verde, Irvine, CA 92612 (US). (74) Agent: ELBING, Karen, L.; Clark & Elbing LLP, 176 Federal Street, Boston, MA 02110-2214 (US). | | (81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i> |
| (54) Title: FLUORESCENT AMYLOID A β PEPTIDES AND USES THEREOF (57) Abstract Disclosed herein are aggregating amyloid A β peptides which are covalently bonded (for example, at a cysteine amino acid residue) to a fluorescent label, and methods for their use. | | |

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

| | | | | | | | |
|----|--------------------------|----|--|----|--|----|--------------------------|
| AL | Albania | ES | Spain | LS | Lesotho | SI | Slovenia |
| AM | Armenia | FI | Finland | LT | Lithuania | SK | Slovakia |
| AT | Austria | FR | France | LU | Luxembourg | SN | Senegal |
| AU | Australia | GA | Gabon | LV | Latvia | SZ | Swaziland |
| AZ | Azerbaijan | GB | United Kingdom | MC | Monaco | TD | Chad |
| BA | Bosnia and Herzegovina | GE | Georgia | MD | Republic of Moldova | TG | Togo |
| BB | Barbados | GH | Ghana | MG | Madagascar | TJ | Tajikistan |
| BE | Belgium | GN | Guinea | MK | The former Yugoslav Republic of Macedonia | TM | Turkmenistan |
| BF | Burkina Faso | GR | Greece | ML | Mali | TR | Turkey |
| BG | Bulgaria | HU | Hungary | MN | Mongolia | TT | Trinidad and Tobago |
| BJ | Benin | IE | Ireland | MR | Mauritania | UA | Ukraine |
| BR | Brazil | IL | Israel | MW | Malawi | UG | Uganda |
| BY | Belarus | IS | Iceland | MX | Mexico | US | United States of America |
| CA | Canada | IT | Italy | NE | Niger | UZ | Uzbekistan |
| CF | Central African Republic | JP | Japan | NL | Netherlands | VN | Viet Nam |
| CG | Congo | KE | Kenya | NO | Norway | YU | Yugoslavia |
| CH | Switzerland | KG | Kyrgyzstan | NZ | New Zealand | ZW | Zimbabwe |
| CI | Côte d'Ivoire | KP | Democratic People's Republic of Korea | PL | Poland | | |
| CM | Cameroon | KR | Republic of Korea | PT | Portugal | | |
| CN | China | KZ | Kazakhstan | RO | Romania | | |
| CU | Cuba | LC | Saint Lucia | RU | Russian Federation | | |
| CZ | Czech Republic | LI | Liechtenstein | SD | Sudan | | |
| DE | Germany | LK | Sri Lanka | SE | Sweden | | |
| DK | Denmark | LR | Liberia | SG | Singapore | | |
| EE | Estonia | | | | | | |

FLUORESCENT AMYLOID A β PEPTIDES AND USES THEREOF

Background of the Invention

5 In general, the invention features fluorescent A β peptides and methods for their use.

 The extracellular deposition of β -amyloid in senile plaques is one of the neuropathological hallmarks of Alzheimer disease (AD). The major constitutive component of amyloid plaques is the A β peptide, a 39 to 43 residue
10 polypeptide (Selkoe et al., (1986) *J. Neurochem.* 46:1820-1834) that is proteolytically derived from the amyloid precursor protein (APP), a much larger type I transmembrane protein. A β is folded into the β -sheet structure that is characteristic of amyloid fibrils.

 Amyloid plaque formation likely involves two basic steps: the initial
15 formation of a seeding aggregate that establishes the amyloid fibril lattice (Kirschner et al., (1987) *Proc. Natl. Acad. Sci. USA* 84:6953-6957), followed by the elongation of the fibril by the sequential addition of subunits (Maggio et al., (1992) *Proc. Natl. Acad. Sci. USA* 89:5462-5466). Some of the key parameters that promote the assembly of amyloid fibril include high peptide
20 concentration, long incubation time, low pH (pH 5-6) (Barrow et al., (1991) *Science* 253:179-182; Burdick et al., (1992) *J. Biol. Chem.* 267:546-554; and Fraser et al., (1991) *Biophys. J.* 60:1190-1201), solvent composition (Shen and Murphy, (1995) *Biophysical J.* 69:640-651), and salt concentration (Hilbich et al., (1991) *J. Mol. Biol.* 218:149-163). Assembly of A β into the fibrils may
25 also be promoted by molecules that interact with A β and increase its rate of aggregation *in vitro* including ApoE (Strittmatter et al., (1993) *Proc. Natl. Acad. Sci. USA* 90:8098-8102; and Wisniewski and Frangione, (1992)

-2-

Neurosci. Lett. 135:235-238), α 1-antichymotrypsin (Abraham et al., (1988) *Cell* 52:487-501), complement C1q (Rogers et al., (1992) *Proc. Natl. Acad. Sci. U. S. A.* 89:10016-10020), heparin sulfate proteoglycan (Snow et al., (1988) *Am. J. Pathol.* 133:456-463), and zinc ions (Bush et al., (1994) *J. Biol. Chem.* 5 269:2152-12158; and Bush et al., (1994) *Science* 265:1464-1467).

Although many of the parameters influencing fibril assembly have been elucidated, relatively little is known about the structure of soluble A β . Gel filtration analysis of A β in solution reveals the presence of multiple, discrete structures that have variously been interpreted as monomer, dimer, 10 trimer, and higher order aggregates (Barrow et al., (1992) *J. Mol. Biol.* 225:1075-1093; Bush et al., (1994) *J. Biol. Chem.* 269:2152-12158; Hilbich et al., (1991) *J. Mol. Biol.* 218:149-163; Soreghan et al., (1994) *J. Biol. Chem.* 269:28551-28554; and Zagorski and Barrow, (1992) *Biochemistry* 31:5621-5631). The oligomeric structure depends on the concentration of the peptide, 15 time of incubation, and the length of its carboxyl terminus (Soreghan et al., (1994) *J. Biol. Chem.* 269:28551-28554).

Summary of the Invention

In general, the invention features a composition that includes an aggregating amyloid A β peptide to which is covalently bonded a fluorescent 20 label. In one preferred embodiment, the fluorescent label is covalently bonded to a cysteine amino acid. The invention also features a method for generating such a preferred aggregating amyloid A β peptide. The method involves (a) generating an amyloid A β peptide including a cysteine amino acid substitution; (b) covalently bonding a fluorescent label to the peptide at the cysteine amino 25 acid; and (c) determining whether the peptide is capable of aggregating with another A β peptide.

-3-

In other preferred embodiments, the wild type amyloid A β peptide is a human A β peptide; the amyloid A β peptide has the amino acid sequence of SEQ ID NO: 1 or SEQ ID NO: 2; the cysteine amino acid of the peptide replaces an amino acid in a wild type A β peptide and, for example, replaces an internal amino acid or a hydrophobic amino acid of the peptide. Preferred aggregating A β peptides include, without limitation, those having the sequence of SEQ ID NO: 1 or SEQ ID NO: 2, except that a cysteine replaces either a phenylalanine at position 4, an aspartic acid at position 7, a glycine at position 25, or a leucine at position 34. Preferred fluorescent labels include any thiol-reactive fluorescent dyes (for example, 1,5-IEDANS or fluorescein) or any of the light-emitting moieties chosen from the group consisting of Bodipy, FTC, Texas Red, phycoerythrin, rhodamine, carboxytetramethylrhodamine, DAPI, an indopyras dye, Cascade Blue, Oregon Green, eosin, erythrosin, pyridyloxazole, benzoxadiazole, aminonaphthalene, pyrene, maleimide, a coumarin, NBD, Lucifer Yellow, propidium iodide, a porphyrin, CY³, CY⁵, CY⁹, a lanthanide cryptate, a lanthanide chelate, or a derivative or analog thereof.

The aggregating A β peptides of the invention are useful in methods for detecting or monitoring A β production, accumulation, aggregation, or disaggregation. One particular method for the detection of an amyloid aggregate (for example, an amyloid plaque) involves (a) contacting the sample with an aggregating amyloid A β peptide to which is covalently bonded a fluorescent label; and (b) detecting the fluorescent label in association with the sample as an indication of an amyloid aggregate.

In preferred embodiments, this method is carried out to diagnose Alzheimer's disease or a predisposition thereto; the fluorescent label is covalently bonded to a cysteine amino acid; the cysteine amino acid replaces an amino acid in a wild type A β peptide; the cysteine amino acid replaces a

-4-

hydrophobic amino acid or an internal amino acid in a wild type amyloid A β peptide; the aggregating A β peptide is chosen, without limitation, from peptides having the sequence of SEQ ID NO: 1 or SEQ ID NO: 2, except that a cysteine replaces either a phenylalanine at position 4, an aspartic acid at position 7, a glycine at position 25, or a leucine at position 34; and the fluorescent label is a thiol-reactive fluorescent dye (for example, 1,5-IEDANS or fluorescein) or is chosen from the light-emitting moieties, Bodipy, FTC, Texas Red, phycoerythrin, rhodamine, carboxytetramethylrhodamine, DAPI, an indopyras dye, Cascade Blue, Oregon Green, eosin, erythrosin, pyridyloxazole, benzoxadiazole, aminonaphthalene, pyrene, maleimide, a coumarin, NBD, Lucifer Yellow, propidium iodide, a porphyrin, CY³, CY⁵, CY⁹, a lanthanide cryptate, a lanthanide chelate, or a derivative or analog thereof.

The aggregating A β peptides of the invention also find use in screens for identifying compounds capable of affecting the aggregation of A β amyloid peptide. One particular method involves (a) providing a sample of A β amyloid peptide; (b) contacting the sample with (i) an aggregating amyloid A β peptide to which is covalently bonded a fluorescent label; and (ii) a candidate compound; and (c) measuring association of the fluorescent label with the sample, a change in the level of fluorescent label found in association with the sample relative to a control sample lacking the candidate compound being an indication that the compound is capable of affecting A β amyloid peptide aggregation. In a preferred embodiment of this method, the sample includes unlabeled A β amyloid peptide bound to a solid support, and the aggregation is measured by association of the fluorescent label with the solid support.

The invention also includes a second exemplary method for identifying a compound capable of affecting the aggregation of A β amyloid peptide. This method involves (a) providing a sample of an aggregating

-5-

amyloid A β peptide to which is covalently bonded a fluorescent label; (b) contacting the sample with a candidate compound; and (c) measuring the ability of the peptide to aggregate, a change in the amount of aggregated peptide in the presence of the candidate compound relative to a sample lacking
5 the compound being an indication that the compound is capable of affecting A β amyloid peptide aggregation.

In preferred embodiments of both of the above screening methods, the fluorescent label is covalently bonded to a cysteine amino acid; the cysteine amino acid replaces an amino acid in a wild type A β peptide; the cysteine
10 amino acid replaces a hydrophobic amino acid or an internal amino acid in a wild type amyloid A β peptide; the aggregating A β peptide is chosen, without limitation, from peptides having the sequence of SEQ ID NO: 1 or SEQ ID NO: 2, except that a cysteine replaces either a phenylalanine at position 4, an aspartic acid at position 7, a glycine at position 25, or a leucine at position 34;
15 the fluorescent label is a thiol-reactive fluorescent dye (for example, 1,5-IEDANS or fluorescein) or is chosen from the group of light-emitting moieties consisting of Bodipy, FTC, Texas Red, phycoerythrin, rhodamine, carboxytetramethylrhodamine, DAPI, an indopyras dye, Cascade Blue, Oregon Green, eosin, erythrosin, pyridyloxazole, benzoxadiazole, aminonaphthalene,
20 pyrene, maleimide, a coumarin, NBD, Lucifer Yellow, propidium iodide, a porphyrin, CY³, CY⁵, CY⁹, a lanthanide cryptate, a lanthanide chelate, or a derivative or analog thereof; and aggregation is measured by centrifugation, gel filtration, or fluorescence resonance energy transfer (FRET) analysis.

As used herein, by an "amyloid A β peptide" is meant any β -amyloid
25 peptide or fragment thereof which aggregates under physiological conditions (for example, as tested herein).

By a "wild type" A β peptide is meant any naturally occurring β -

-6-

amyloid peptide.

By an "aggregating" amyloid A β peptide is meant that, under physiological conditions, the peptide (which is fluorescently labeled) exhibits at least 70%, preferably at least 80%, more preferably at least 90%, and most
5 preferably at least 95% of the aggregate formation exhibited by a corresponding unlabeled peptide under identical conditions.

By an "internal amino acid" is meant any amino acid of a peptide except the amino-terminal or carboxy-terminal residues.

The present invention provides a number of advantages. Most
10 notably, because the peptides described herein represent the first examples of fluorescently labeled A β peptides that exhibit wild type aggregation properties, this invention enables any number of diagnostic techniques that appropriately monitor amyloid aggregation or disaggregation. In addition, also because of the peptides' wild type aggregation characteristics, the invention enables, for
15 the first time, screening techniques using biologically relevant fluorescent A β peptides for the discovery of compounds that affect amyloid peptide aggregation. Such compounds provide important candidate therapeutics, for example, for the treatment or amelioration of Alzheimer's disease or its symptoms.

20 Other features and advantages of the claimed invention will be apparent from the following detailed description thereof, and from the claims.

Detailed Description of the Invention

The drawings will first briefly be described.

Brief Description of the Drawings

25 Figure 1 is a bar graph illustrating the aggregation properties of

-7-

fluorescent derivatives of A β . The aggregation properties of the fluorescent derivatives were compared with wild type A β under physiological conditions where the wild type peptide was largely soluble (i.e., Tris buffered saline at pH 7.4) and under two additional conditions known to promote fibrillization: pH 5.0 and at pH 7.4 in the presence of 70 μ M Zn⁺⁺ (as described below). The samples were centrifugated after a 48 hour incubation. The amount of sedimentable wild type peptide was determined by scintillation counting, and the amount of sedimentable fluorescent peptide was determined by fluorescence intensity.

Figures 2A-2B are graphs illustrating gel filtration analyses of fluorescent A β . In Figure 2A, chromatogram "a" shows the elution profile of wild type A β as detected by absorbance at 280 nm. Chromatograms "b" and "c" show the elution of A β C25-AEDANS and A β C7-FM, respectively, as detected by fluorescence at 482 nm and 520 nm, respectively. The peptides were dissolved in DMSO for 30 minutes and then ten fold diluted in buffer A at a final protein concentration of 5-10 μ M. A 200 μ l aliquot was loaded onto a Superdex 75HR 10/30 column and eluted at a rate of 0.4 ml/min. The inset in the upper left corner shows the calibration curve for the column using a series of peptide and protein standards as described below. Figure 2B shows the elution profile of 2.0 nM A β ¹⁴C A β run under the same conditions above and detected by scintillation counting.

Figure 3 is a graph illustrating the unfolding of A β measured by tyrosine fluorescence and 1,5-IAEDANS fluorescence. Equilibrium unfolding curves were monitored by measuring the intrinsic tyrosine fluorescence at 308 nm on excitation at 280 nm of wild type A β (solid squares) and A β C25-AEDANS fluorescence at excitation 346 nm (solid circles). The protein concentration was 5-10 μ M of A β .

-8-

Figures 4A and 4B are graphs illustrating the renaturation of A β measured by tyrosine fluorescence and AEDANS fluorescence. The emission spectra of either peptide freshly dissolved in buffer A (---), peptide dissolved in 100% DMSO (—), or peptide dissolved in 100% DMSO and then diluted 10-fold in buffer A (···) are shown. The wild type peptide is presented in Figure 4A, and A β C25-AEDANS is presented in Figure 4B. Emission spectra were recorded from 290 to 400 nm with an excitation at 280 nm for tyrosine fluorescence and 356 to 600 nm with an excitation at 336 nm for A β C25-AEDANS.

Figures 5A-5C are graphs illustrating the association of AEDANS-labeled and FM-labeled A β in dilute aqueous solution as determined by FRET. Figure 5A shows an emission spectrum of an equal molar amount of A β C25-AEDANS (donor) and A β C7-FM (acceptor) mixed in DMSO and then diluted 10-fold in Buffer A (···). The final protein concentration was 3 μ M. The control spectrum (—) corresponds to the mathematical sum of the following control samples: an equal molar mixture of A β C25-AEDANS and A β and an equal molar mixture of A β C7-FM and A β . Efficient FRET is evident by the quenching of the donor and an increased emission of the acceptor. Figure 5B shows the emission spectrum for the other donor-acceptor pair, A β C34-AEDANS and A β C4-FM. Figure 5C shows the emission spectrum of the mixture of A β C25-AEDANS, A β C7-FM plus a 10-fold molar excess of wild type A β (—). The control spectrum (—) corresponds to the arithmetical sum of the controls for donor alone and acceptor alone in the presence of 10 fold excess of wild type peptide. The addition of an excess of unlabeled A β abolished the FRET between A β C25-AEDANS and A β C7-FM.

Figures 6A-6D are graphs illustrating the association of A β -A β Y10W in dilute aqueous solution as determined by FRET. The association

-9-

of A β and A β Y10W in 10% DMSO in Buffer A is shown in Figures 6A and 6B, and the association of these same peptides in 2% DMSO in Buffer A is shown in Figures 6C and 6D. Figures 6A and 6C represent the steady-state emission data, and Figures 6B and 6D represent the corresponding

5 deconvoluted spectra. The traces correspond to the emission spectra of the mixture of A β and A β Y10W (spectrum 1), and the following controls: donor A β alone (spectrum 2) and acceptor A β Y10W alone (Barrow et al., (1991) *Science* 253:179-182). Spectrum 4 represents the mathematical sum of spectra 2 and 3. Spectrum 5 represents the deconvoluted emission spectra of the

10 acceptor in the mixture and is obtained by multiplying spectrum 3 by the factor (F_{DA}/F_A), where F_{DA} is the emission of the acceptor in the mixture and F_A is the emission of the acceptor alone. Spectrum 6 is the deconvoluted emission spectrum of the donor in the mixture and is obtained by subtraction of spectrum 5 from spectrum 1. The A β concentration was 10 μ M. The

15 association of A β and A β Y10W is more readily evident in the deconvoluted spectra in Figures 6B and 6D, as indicated by the quenching of the donor tyrosine and an increase in the emission of the acceptor tryptophan.

Described below are exemplary amyloid A β peptides according to the invention. These peptides are fluorescently labeled and exhibit the

20 aggregation properties of wild type A β peptides. Because of these properties, the peptides described herein find use in diagnostic methods for Alzheimer's disease that involve detection of amyloid plaques by aggregation with the fluorescent A β peptides described herein. The ability of these peptides to aggregate in a fashion similar to wild type A β also enables the design of assays

25 to screen for compounds capable of disrupting fluorescent A β or fluorescent A β -wild type A β aggregates. Finally, the fluorescent A β peptides described

-10-

herein may be used as detection reagents in any standard fluorescence anisotropy or fluorescence polarization technique.

The following examples are provided for the purpose of illustrating the invention, and should not be construed as limiting.

5

EXAMPLE 1
Synthesis and Characterization
of Fluorescent A β Peptides

The A β peptides of the invention were chemically synthesized, fluorescently labeled, and characterized as follows.

10 Synthesis and Aggregation Properties of Fluorescent A β Peptides

A series of A β variants containing a single cysteine substitution were chemically synthesized as described below. Cysteine was chosen because of its unique chemical reactivity and its absence in the wild type A β sequence (SEQ ID NO: 1). Initially, a series of cysteine substitutions were synthesized by
15 replacing every third residue because the cysteine side chain was expected to alternate on opposite sides of the strand in a beta sheet structure. The cysteine-containing probe peptides were covalently labeled with a variety of extrinsic fluorescent probes. Mass spectrometry confirmed the expected mass of the final product, and the absence of the precursor peptide indicated that the
20 labeling reaction was complete. A peptide containing tryptophan instead of tyrosine at position 10 was also synthesized to use as an acceptor for intrinsic tyrosine fluorescence of the wild type peptide.

The aggregation properties of the fluorescent derivatives were compared to wild type A β under physiological conditions (e.g., Tris buffered
25 saline at pH 7.4) where the peptide was largely soluble, as well as under conditions that were known to promote fibril assembly (e.g., pH 5.0 and pH 7.4 in the presence of Zn⁺⁺) (Fig. 1). As shown in Figure 1, at pH 7.4 and at pH

-11-

5.0, all of the fluorescent peptides were indistinguishable from wild type A β . In the presence of 70 μ M Zn⁺⁺, the fluorescein and AEDANS labeled A β peptides aggregated to approximately 50-75% of the extent of wild type A β . However trp substitution at residue 10 did not alter the aggregation behavior in response to Zn⁺⁺. The oligomeric structure of the fluorescent peptides was characterized by gel filtration, and the fluorescent peptides were found to elute at the same position as wild type A β (Figs. 2A and 2B). The elution position corresponded to an apparent molecular mass of 9,000 Da established by the elution behavior of a series of calibration standards (Fig. 2A, inset). The calibration curve also indicated that the expected elution position for a peptide of the mass of monomeric A β was well separated from the observed elution position of A β . Nanomolar concentrations of ¹⁴C-labeled A β 1-40 also eluted at the position expected for a dimer (Fig. 2B).

Denaturation and Renaturation of A β in DMSO

In order to analyze the structure of soluble A β by fluorescence resonance energy transfer (FRET), conditions were established for the denaturation and renaturation of A β . Previous studies using a combination of Fourier transform infrared spectroscopy, and dynamic light scattering (Shen and Murphy, (1995) *Biophysical J.* 69:640-651; and Snyder et al., (1994) *Biophys. J.* 67:1216-1228) demonstrated that A β was denatured and monomeric in DMSO. The intrinsic fluorescence of proteins provides a signal commonly used to monitor conformational changes and unfolding (Wu et al., (1994) *Biochemistry* 33:7415-74222). In the present work, the intrinsic tyrosine fluorescence of wild type A β was used to assay the denaturation of A β in DMSO, and its renaturation. The tyrosine emission of most native proteins and peptides is frequently small or undetectable due to the presence of more highly fluorescent tryptophan residues (Lakowicz, (1983) *Principles of Fluorescence*,

-12-

Plenum Press, New York, N.Y.; and Wu et al., (1994) *Biochemistry* 33:7415-74222), but tryptophan is absent in A β .

The denaturation curve for wild type A β showed a single, smooth cooperative transition (Fig. 3). Increasing concentrations of DMSO increased the intrinsic fluorescence intensity of A β , indicating that a significant increase in the exposure of the tyrosine residue occurred in the unfolded state. The midpoint of intrinsic fluorescence changes occurred at approximately 40% DMSO. The emission maximum of tyrosine was not affected by DMSO, remaining the same at all concentrations (i.e., 308 nm) because the tyrosine fluorescence emission maximum was not sensitive to the polarity of the solvent (Lakowicz, (1983) *Principles of Fluorescence, Plenum Press, New York, N.Y.*). The data described herein were corrected for the relatively small solvent effect of DMSO on free tyrosine to ensure that the curve accurately reflected the unfolding of A β .

Having determined the above parameters for wild type A β , the denaturation of the extrinsically-labeled fluorescent A β probes was also examined. For environment-sensitive fluorophores (like 1,5-IAEDANS) the emission maximum shifts to a shorter wavelength (blue shift) as the polarity of the surrounding environment decreases (Lakowicz, (1983) *Principles of Fluorescence, Plenum Press, New York, N.Y.*). Conversely the emission maximum shifts to the longer wavelengths (red shift) in a more polar environment. For A β C25-AEDANS, a marked blue-shift (42 nm) of the emission was observed upon unfolding by DMSO (Fig. 3), indicating that the fluorophore was increasingly exposed to the surrounding media at increasing DMSO concentrations. As with the intrinsic tyrosine fluorescence, the midpoint of the blue shift of AEDANS occurred at approximately 50% DMSO. The unfolding transition was complete within 2 hours, and identical unfolding

-13-

curves were obtained for the other fluorescent-labeled A β peptides, A β C4FM, A β C34AEDANS, and A β C7FM. At concentrations of DMSO below 10%, there was little further change in the intrinsic fluorescence emission of A β or the extrinsic fluorescence of A β C25-AEDANS (Fig. 3). These results indicated
5 that AEDANS-labeled and wild type A β peptides had similar stabilities and suggested that there was relatively little change in the overall structure of A β over the range of DMSO from 0% - 10%.

The renaturation of A β from DMSO solution was also examined. Upon 10-fold dilution of DMSO into aqueous buffer solution, the emission
10 spectrum of wild type A β and A β labeled with 1,5-IAEDANS (AEDANS-A β C25) showed the same maximum at 308 nm and 494 nm as observed for the peptides dissolved directly in Buffer A, indicating that the denatured peptide returned to the same overall structure (Figs. 4A and 4B). Time course studies indicated that the refolding of the peptide was immediate. When the DMSO
15 was diluted 50-fold (2% DMSO), the emission spectrum of the refolded peptide was indistinguishable from the emission spectrum of the A β dissolved directly in aqueous buffer, suggesting that the denatured peptide recovered the same structure. Both samples in 10% and 2% DMSO displayed the same elution time by gel filtration. Similar denaturation and renaturation results were
20 obtained with guanidinium hydrochloride (GdnHCl). DMSO stock solutions of peptide were employed for all of the subsequent experiments.

Association of Fluorescent A β Peptides

Fluorescence resonance energy transfer between AEDANS and fluorescein was used initially to monitor association of A β monomers
25 following dilution of DMSO into aqueous buffer solution. For these experiments, A β C25-AEDANS and A β C7-FM DMSO stock solutions were mixed 1:1 (donor:acceptor), and subsequently ten fold diluted in Buffer A. The

-14-

final concentration of the peptide was 3 μ M. The resulting fluorescence spectra are shown in Figure 5A. Efficient FRET was observed, as evidenced by a quenching of the donor emission at 474 nm and an increase in the acceptor fluorescence at 520 nm, compared to the control spectra, indicating that hybrid
5 A β dimers had formed in the mixture containing both donor and acceptor (Fig. 5A). The efficiency of FRET did not change significantly upon subsequent incubation for 24 hours.

In order to control for possible effects of peptide structure on the fluorescence intensity of labeled peptides, control measurements were carried
10 out in which either A β C25-AEDANS or A β C7 FM were individually mixed with an equal amount of non-labeled peptide in DMSO, and then diluted 10-fold in Buffer A. The emission spectra obtained for A β C25-AEDANS or A β C7 FM are shown as arithmetic sums of the individual spectra (i.e., the expected emission in the absence of energy transfer). Efficient FRET was also
15 observed with several other pairs of A β peptides (Table I).

Figure 5B shows the spectra of the energy transfer experiment where another donor-acceptor pair, A β C34-AEDANS--A β C4-FM, was used. The efficiency of FRET for this combination was higher than that observed for A β C25 AEDANS and A β C7 FM, suggesting that the peptide structure was
20 ordered and that the fluorophores at positions 34 and 4 may be in closer proximity in the structure than those at positions 25 and 7. Once formed, the A β dimers appeared to be relatively stable in solution. If fluorescent homodimers were formed first by individually diluting stock solution 10-fold into Buffer A, and then subsequently mixed, no resonance energy transfer was
25 observed over an incubation of 24 hours, indicating that subunit exchange between homodimers was not detectable over this period.

Several controls were conducted to ensure that the FRET observed

-15-

was due to interactions between peptides that occurred in solution with wild type A β . After each FRET experiment, we confirmed that the fluorescent peptide mixture eluted at the same apparent dimer position as the wild type peptide by gel filtration chromatography. It was also determined that FRET
5 was nearly abolished when a 10-fold molar excess of wild type peptide was added to the fluorescent peptide mixture in DMSO and then subsequently diluted (Fig. 5C), indicating that the wild type peptide could compete for the fluorescent peptides and form fluorescent and wild type A β heterodimers that did not exhibit FRET. Lastly, the endogenous tyrosine fluorescence of wild
10 type A β was exploited as a donor for A β in which tryptophan replaced the tyrosine at position 10 (A β Y10W).

Efficient FRET was also observed for the mixture of A β and A β Y10W (Fig. 6). This experiment was conducted under two different conditions: (i) where the mixture was diluted to 10% DMSO (Figs. 6A and 6B)
15 and (ii) where the mixture was diluted to 2% DMSO (Figs. 6C and 6D). A deconvolution analysis of FRET between A β and A β Y10W was conducted as reported (Soreghan et al., (1994) *J. Biol. Chem.* 269:28551-28554) (Figs. 6B and 6D). As shown in Table 1, the efficiency of FRET was found to be significantly higher in 2% DMSO than in 10% DMSO, suggesting that the
20 structure in 10% DMSO might be partially unfolded.

-16-

Table 1

Efficiencies of Energy Transfer for Different Donor-Acceptor Pairs

| | Donor-Acceptor pair | <i>E</i> (efficiency of energy transfer) | %DMSO |
|---|---------------------|--|-------|
| 5 | AβC25I-AβC7FM | 0.14 | 10 |
| | AβC34I-AβC4FM | 0.20 | 10 |
| | Aβ-ABY10W | 0.21 | 10 |
| | Aβ-ABY10W | 0.46 | 2 |

- 10 Our experiments with three different donor-acceptor pairs demonstrated that efficient FRET was observed when the peptides were mixed in DMSO prior to dilution in aqueous buffer, suggesting that they formed dimers in solution. It was conceivable that the aggregates might actually represent higher order structures (e.g., trimers or tetramers). We measured the
- 15 lifetime of the FM-labeled Aβ by phase modulation frequency domain methods in the range 3 μM - 100 nM. The fluorescence lifetime data fit to a single decay exponential that remained constant over the concentration range. This suggested that there was a single distance between the fluorophores, and that it did not change over the concentration range examined. A single distance
- 20 would be expected in a population of structurally homogenous dimers, while higher order aggregates would have to be radially symmetrical to obtain a single distance. Taken together with the gel filtration data, the simplest conclusion is that Aβ exists as a stable dimer over the concentration range from nM to μM.

-17-

Additional Aggregating A β Peptides

In addition to the A β peptides described above, an extended A β peptide was generated having the following sequence:

DAEFRHDSGYEVHHQKLVFFAEDVGSNKGAIIGLMVGGVVIA (SEQ ID

- 5 NO: 2). This peptide was chemically synthesized and fluorescently labeled (as described above) at the amino acid positions described above. These fluorescent derivatives were found to form fibrils, to aggregate, and to bind cells in a manner analogous to the unlabeled wild type peptide.

Summary of Fluorescent A β Peptide Characteristics

- 10 In sum, the fluorescently labeled peptides described herein possess properties characteristic of wild type A β . In particular, the elution behavior of the fluorescent peptides on gel filtration was identical to wild type A β , indicating that the fluorescent peptides had the same hydrodynamic radius in solution. In addition, denaturation-renaturation experiments demonstrated that
- 15 the stability of the fluorescent peptides was indistinguishable from the wild type peptide. Moreover, when the aggregation properties of the fluorescent peptides were assayed, they were found to be nearly identical to the wild type peptides. And, lastly, experiments employing several different combinations of donor and acceptor peptides, labeled at different positions, indicated that all
- 20 tested peptides behaved as dimers.

- The finding that A β formed a stable dimer in solution suggests that dimerization is the initial event in amyloid aggregation and that it represents the fundamental building block for further fibril assembly as has been previously proposed (Shen and Murphy, (1995) *Biophysical J.* 69:640-651; and Soreghan
- 25 et al., (1994) *J. Biol. Chem.* 269:28551-28554). This model of amyloid assembly is very similar to the model recently proposed for immunoglobulin light chain amyloid fibrils on the basis of molecular modeling studies (Stevens

-18-

et al., (1995) *Biochemistry* 34:10697-10702). In this model, the two light chains align in a parallel fashion creating a dimer with a 2-fold axis of symmetry. It seems likely that the A β dimer may also have the same arrangement because it behaves as if it is axially amphipathic with one end polar and the other end hydrophobic (Soreghan et al., (1994) *J. Biol. Chem.* 269:28551-28554). This implies that at least some of the dimer may be arranged in a parallel fashion, because if the dimer were arranged in a simple head to tail fashion, as has been previously proposed (Lakowicz, (1983) *Principles of Fluorescence*, Plenum Press, New York, N.Y.), the hydrophobic moment of the resulting dimer might be expected to be symmetric with respect to the ends of the dimer. Previous CD and FTIR spectroscopic studies indicate that soluble A β has substantial β -sheet content, suggesting that the dimer adopts a beta structure (Barrow et al., (1991) *Science* 253:179-182; Barrow et al., (1992) *J. Mol. Biol.* 225:1075-1093; Shen and Murphy, (1995) *Biophysical J.* 69:640-651; and Zagorski and Barrow, (1992) *Biochemistry* 31:5621-5631).

In the amyloid light chain model, the next step in polymerization is head to tail association of dimers related by a 90° rotation around the 2-fold axis to form a tetramer that establishes a "proamyloid" filament lattice that is capable of propagating filaments of indefinite length. Elongation of the fibril is accomplished by the stepwise addition of dimers onto the filament. This "proamyloid" filament may correspond to the " β crystallite" proposed for A β from fibril diffraction measurements (Inouye et al., (1993) *Biophys. J.* 64:502-19) and observed in atomic force microscopy images (Stine et al., (1996) *J. Protein Chem.* 15:193-203). In this step, the free energy contribution of individual amino acid side chains is effectively doubled because of the 2-fold symmetry of the interacting surfaces (Stevens et al., (1995) *Biochemistry* 34:10697-10702). It seem likely that A β is also capable of forming a similar

-19-

stable tetramer. Discrete aggregate species migrating at the position expected for a tetramer have been observed by SDS PAGE in samples of A β 1-42 (Burdick et al., (1992) *J. Biol. Chem.* 267:546-554; and Soreghan et al., (1994) *J. Biol. Chem.* 269:28551-28554). In A β , the formation of this SDS-resistant
5 higher order aggregate depends on the length of the carboxyl terminus of A β (e.g. only A β 1-42 and A β 1-43), and it is also concentration dependent, occurring at approximately the critical micelle concentration defined by surface tension measurements (Soreghan et al., (1994) *J. Biol. Chem.* 269:28551-28554). These results suggest that the formation of higher order aggregates in
10 A β may be mediated predominantly by hydrophobic contacts.

The formation of amyloid fibrils in the light chain model is proposed to proceed by the lateral association of the "proamyloid" filaments or subfibrils (Stevens et al., (1995) *Biochemistry* 34:10697-10702). This step corresponds mechanistically to the formation of the nucleating center proposed for A β
15 (Jarrett et al., (1993) *Biochemistry* 32:4693-4697). Evidence for the existence of subfibrils has been obtained for A β by rapid-freeze, deep-etch electron microscopy (Miyakawa and Kuramoto, (1989) *Ann. Med.* 21:99-102) and more recently by atomic force microscopy (Stine et al., (1996) *J. Protein Chem.* 15:193-203). In the light chain model, four strands are proposed to
20 associate in an antiparallel fashion, but it is not clear how many subfibrils are contained within A β fibrils. The number of subfibrils for amyloid A β fibrils is not clear, but electron micrographs show images that appear to contain 5 subfibrils and this number gives the best fit in modeling the observed reflections in fiber diffraction studies (Inouye et al., (1993) *Biophys. J.* 64:502-
25 19). It is also conceivable that this number could vary within a population of A β fibrils and this could account for differences in the diameter and morphology of fibrils that has been reported (Stine et al., (1996) *J. Protein*

-20-

Chem.15:193-203), as well as the fact that sheet and ribbon morphologies are also known to occur in synthetic A β aggregates (Burdick et al., (1992) *J. Biol. Chem.* 267:546-554; and Halverson et al., (1990) *Biochemistry* 29:2639-2644). Other than the initial dimerization event, the details of this model of amyloid
5 fibril formation remain to be verified experimentally for A β .

Fluorescent derivatives of A β are also useful for exploring other aspects of amyloid structure. For example, quantitative measurements of distances between fluorescent dipoles by FRET are possible (Lakowicz, (1983) *Principles of Fluorescence, Plenum Press, New York, N.Y.*). The fact that A β
10 forms a dimer in solution simplifies the interpretation of FRET measurements, because there is only one distance between fluorophores in a dimer. If a sufficient number of distance measurements are available, it may be possible to discern the structural organization of the polypeptide within the dimer, albeit at a lower resolution than might be achievable by X-ray crystallography or NMR.
15 Until now, this is the first report in which A β amyloid intrinsic fluorescence and FRET between A β fluorescent derivatives have been used to study amyloid structure. Different fluorescent A β analogs may also be useful for mapping the solvent-accessible surface of the amyloid fibril by quenching studies (Lakowicz, (1983) *Principles of Fluorescence, Plenum Press, New York, N.Y.*).

20 Moreover, as discussed above, since the aggregation state of A β has been shown to be important for *in vitro* toxicity, molecules that inhibit A β aggregation provide candidates for therapeutic strategies based on blocking amyloid deposition. Examples of therapeutic inhibitors are molecules that bind tightly with A β monomer and prevent dimerization and molecules that prevent
25 oligomerization of dimers or the extension of fibrils.

Materials

All A β peptides analogs were synthesized by fluoren-9-ylmethoxy

-21-

carbonyl chemistry using a continuous flow semiautomatic instrument as described previously (Burdick et al., (1992) *J. Biol. Chem.* 267:546-554). The peptides were purified by reverse phase high performance liquid chromatography, and the purity and expected structure was verified by

5 electrospray mass spectrometry. Only peptides exhibiting 90% or greater purity with less than 5% of a single contaminant were used. The wild type sequence on which these peptides were based was

DAEFRHDSGYEVHHQKLVFFAEDVGSNKGAIIGLMVGGVV (SEQ ID NO: 1). The sequence of the extended A β peptides was

10 DAEFRHDSGYEVHHQKLVFFAEDVGSNKGAIIGLMVGGVVIA (SEQ ID NO: 2). Cysteine substitution mutants were synthesized simultaneously by the same method, except that, at locations where cysteine was substituted, a portion of the resin was coupled separately with cysteine. ^3H -A β and ^{14}C -A β were synthesized by incorporation of Fmoc- ^3H -Phe or Fmoc- ^{14}C -Ala at positions 4

15 and 2 respectively, yielding specific activities of 200 mCi/mmol for ^3H -A β and 36 mCi/mmol for ^{14}C -A β . 1,5-IAEDANS and FM were obtained from Molecular Probes (Eugene, OR). All other reagents were of the highest analytical grade commercially available. A shorthand notation is used herein to refer to the A β analogs that indicates the position of the cysteine substitution

20 with the understanding that all peptides are 40 residues long, and the rest of the sequence is that of wild type A β as described in the abbreviations list.

Fluorescence Labeling of Mutant A β Peptides with 1,5-IAEDANS and FM

Since A β peptides were modified with a single cys at different positions, the sulfydryl-specific reagents FM and 1,5-IAEDANS were used to

25 prepare fluorescent derivatives. The A β analog peptides were dissolved in 10 mM MOPS pH 8.5 at a concentration of 25 μM (pH 7.4 in the case of fluorescein labeling). 1,5-IAEDANS or FM was added to this solution from a

-22-

stock solution of 10 mM at a twenty fold (for 1,5-IAEDANS) or 5-fold (for FM) molar excess over A β . The reaction was allowed to proceed at room temperature in the dark for 6 hours. Free fluorophore was then removed by filtration on a Sephadex G-25 column equilibrated with 10 mM MOPS at pH 7.4. Labeled A β was aliquoted, lyophilized, and stored at -20°C. Protein was determined by Coomassie R Protein Assays Reagent (Pierce, Rockford, IL). The concentrations of 1,5-IAEDANS or FM were spectrophotometrically determined by using their molar extinction coefficients (5,7 mM⁻¹ at 336 nm or 83 mM⁻¹ at 490 nm, respectively). The labeling stoichiometry of the final products was 1.0. The stoichiometry was confirmed by laser desorption mass spectrometry that demonstrated that all of the precursor had been converted to a mass appropriate for fluorescent peptide.

Aggregation Measurements

Aggregation was determined using a sedimentation assay as previously described (Burdick et al., (1992) *J. Biol. Chem.* 267:546-554). ³H-A β (CPM) was mixed with 5 μ M fluorescent A β and unlabeled A β at a total concentration of 95 μ M and incubated for 48 hours. The amount of sedimentable wild type peptide was determined by scintillation counting, and the amount of sedimentable fluorescent peptide was determined by fluorescence intensity as described herein.

Gel Filtration Chromatography

Gel filtration analysis was performed with a Pharmacia Superdex 75 HR 10/30 column using a Waters 490 multiple wavelength UV absorbance detector and Hewlett Packard 3250 fluorescence detector. Data were collected with a Waters Maxima chromatography data system. The running buffer used was 50 mM Tris, 0.1 M NaCl, pH 7.4 (Buffer A) in the presence of 10% or 2% DMSO. The column was calibrated with the following molecular weight

-23-

standards: thyroglobulin, bovine serum albumin, ovalbumin, soybean trypsin inhibitor, ubiquitin, aprotinin, and insulin β -chain. The peptides were detected by UV absorbance at 280 nm and by fluorescence at 482 and 520 nm for IAEDANS and FM respectively.

5 Denaturation of A β in DMSO and Refolding

11 μ M A β or A β C25AEDANS was incubated in increasing concentrations of DMSO, for 1 hour at 24°C. Emission spectra were recorded from 290 to 400 nm upon excitation at 280 nm (or from 340 to 620 nm upon excitation at 336 nm for A β C25AEDANS). Equilibrium was reached after 2
10 hours of incubation in DMSO. For refolding experiments, samples were incubated in 100% DMSO for 1 hour at room temperature, and refolding was initiated by ten or fifty times dilution of the solvent in Tris buffered solution. The concentration of peptide ranged between 3 and 10 μ M.

Absorption and Fluorescence Measurements

15 Absorption measurements were measured with a Perkin Elmer Lambda 3B UV-Vis spectrophotometer. Fluorescence spectra (excitation band pass 4 nm; emission band pass 8 nm) were measured either on an Aminco SLM 48000 or a SPEX Fluorolog F112A spectrofluorometer. Intrinsic tyrosine
20 fluorescence was measured from 285 to 400 nm upon excitation at 275 nm. For A β C25-AEDANS or in energy transfer experiments excitation was at 330 nm, and the spectra were obtained from 340 to 620 nm. The lifetime measurements for FM were acquired using the 488 nm line of argon ion laser for excitation using a multiharmonic frequency-domain spectrofluorometer (Aminco 48000S).

25 Fluorescence Resonance Energy Transfer

The efficiency (E) of fluorescence resonance energy transfer ($FRET$) between probes was determined by measuring the fluorescence intensity of the

-24-

donor (A β C-AEDANS or A β) both in the absence (F_d) and presence (F_{da}) of the acceptor (A β C-FM or A β Y10W), as given by:

$$E = 1 - F_{da} / F_d$$

The efficiency of FRET depends on the inverse sixth power of the distance
 5 between donor and acceptor (Lakowicz, (1983) *Principles of Fluorescence*,
Plenum Press, New York, N.Y.). This allows FRET measurements to be used
 with high sensitivity to follow the association of fluorescent-labeled A β
 monomers during refolding of the peptide in aqueous solution. Stock solutions
 of peptide in DMSO were mixed at an equal molar ratio and diluted 10-fold or
 10 50-fold into 50mM Tris, pH 7.4, 0.1 M NaCl, and the fluorescence spectra was
 recorded at various times after dilution. Controls included the donor and
 acceptor peptides diluted separately and the donor and acceptor mixed with a
 10-fold excess of A β .

Abbreviations

15 The following abbreviations are used herein:

1,5-IAEDANS - 5-(2-((iodoacetyl)amino)ethyl) aminonaphthylene-1-sulfonic
 acid

FM - Fluorescein maleimide

DMSO - Dimethylsulfoxide

20 A β C25AEDANS - A β with cys in position 25 and labeled with 1,5-IAEDANS

A β C7FM - A β with cys in position 7 and labeled with FM

A β C34AEDANS - A β with cys in position 34 and labeled with 1,5-IAEDANS

A β C4FM - A β with cys in position 4 and labeled with FM

A β Y10W - A β with trp in position 10.

25 Additional Fluorescent A β Peptides

Other fluorescently labeled A β peptides possessing the aggregation
 properties of wild-type A β may be synthesized and tested using the techniques

-25-

described above. In particular, other cysteine-substituted peptides may be made, fluorescently labeled, and tested for aggregation properties (for example, by centrifugation, gel filtration, or FRET analysis). In preferred examples, using the methodologies described herein, A β peptides may be cysteine-

5 substituted and fluorescently labeled at any hydrophobic amino acid position. Alternatively, A β peptides may be labeled at the free amino group. In addition, A β peptides may be produced which have multiple sites labeled, if desired, with different fluorescent tags. Again, aggregation activity is tested, for example, as described herein.

10 A β fragments having cysteine substitutions (for example, those substitutions described above) may also be synthesized, fluorescently labeled, and tested for activity. One preferred A β fragment includes amino acids 10-25 of SEQ ID NO: 1.

In addition, any other appropriate fluorescent label may be utilized

15 for peptide synthesis and the methods of the invention. Preferred fluorescent labels include, without limitation, any fluorescent label having a thiol-reactive group. Such fluorescent labels include, for example, thiol-reactive BODIPY, fluorescein, Oregon Green, tetramethylrhodamine, eosin, erythrosin, coumarin, pyridyloxazole, benzoxadiazole, aminonaphthalene, pyrene, maleimide, a

20 lanthanide cryptate, a lanthanide chelate, and Texas Red derivatives (commercially available, for example, from Molecular Probes, Eugene, OR).

EXAMPLE 2

Methods of Use for Fluorescently Labeled Amyloid A β Peptides

25 Because the fluorescently labeled peptides described herein possess aggregation properties characteristic of wild type A β peptides, they provide

-26-

useful reagents for detecting or monitoring the formation or existence of amyloid plaques as a means of diagnosing Alzheimer's disease or a predisposition thereto. In one particular example, a test sample of affected tissue (for example, neuronal or vascular tissue) is obtained from a patient.

- 5 This tissue is then combined with a fluorescent peptide of the invention under conditions that allow A β aggregation (for example, those conditions described herein). The sample is washed to remove unbound peptide, and detection of the fluorescent label in association with the tissue sample is taken as an indication that A β deposits are present in the patient sample. In these assays, a
- 10 negative control sample that is free of amyloid plaques (for example, from an unaffected individual) and one or more positive control samples containing known quantities of amyloid plaques are preferably assayed in parallel, and the results from the patient sample compared to those controls. If desired, in these assays, the degree of fluorescent output may be quantitated by standard
- 15 techniques as an indication of the extent of amyloid plaque formation. This technique is particularly useful for monitoring the progression of disease in an Alzheimer's patient, or the amelioration of disease in response to therapeutic treatment.

- For this assay, patient tissue samples may be obtained from any site
- 20 at which amyloid plaques have been shown to occur including, without limitation, any brain tissue (for example, cerebral cortex, amygdala, and hippocampal tissue), vascular tissue, or neuronal tissue (for example, nasal epithelium). Tissue samples may be tested as thin sections or tissue homogenates. Fluorescent peptide may be added at any appropriate
- 25 concentration, preferably between 0.1 μ M and 25 μ M, and more preferably between 0.1 μ M and 3 μ M. Measurement of fluorescent output is accomplished by any standard technique, for example, fluorescence microscopy

-27-

or flow cytometry. Preferred fluorescent labels for diagnostic use include, without limitation, any thiol-reactive probe, for example, any BODIPY, fluorescein, Oregon Green, tetramethylrhodamine, eosin, erythrosin, coumarin, pyridyloxazole, benzoxadiazole, aminonaphthalene, pyrene, maleimide, a
5 lanthanide cryptate, a lanthanide chelate, or Texas Red derivative (commercially available, for example, from Molecular Probes, Eugene, OR).

In addition to diagnostic utilities, the fluorescent peptides described herein are also useful as reagents for screening assays for the identification of compounds that modulate A β aggregation. Typically, such screening assays
10 are carried out for the purpose of isolating or identifying compounds that inhibit A β aggregation, but may also be used to identify compounds that enhance aggregation.

In one approach, a fluorescent peptide of the invention is placed in contact with an amyloid plaque (for example, from a patient sample) under
15 conditions that allow aggregation. The complex is then treated with candidate modulatory compounds (preferably, inhibitory compounds), and those compounds which affect the ability of the fluorescent peptide to aggregate with the amyloid plaque are selected. With respect to inhibitory compounds, candidate compounds may be added following aggregation of the fluorescent
20 peptide with the amyloid plaque to identify those compounds capable of disrupting or disaggregating existing plaques. Alternatively, the candidate compound may be added to a plaque sample at the same time as the fluorescent peptide to identify compounds capable of interfering with further plaque formation. In these assays, aggregation is measured by association of
25 fluorescent label with the tissue sample. As discussed above, the amyloid plaque used in this assay may be presented as a tissue sample (for example, a thin section), or a tissue homogenate may be used. Also, as discussed above,

-28-

an untreated sample may be used for comparison purposes in these assays.

In an alternative approach to the identification of modulatory compounds, aggregation of the fluorescent peptides of the invention may be assayed directly, with changes in aggregation pattern, conditions, or reaction times used to identify modulatory compounds. As described herein, the fluorescent A β peptides of the invention exhibit aggregation properties characteristic of wild type A β . Accordingly, candidate compounds may be added to a solution of fluorescent A β , either before or after initiation of peptide aggregation, and compounds identified that modulate the ability of these peptides to aggregate. Fluorescent A β aggregation is measured by any appropriate means, for example, any of the methods described herein including, without limitation, fluorescence resonance energy transfer, centrifugation, or gel filtration. Alternatively, unlabeled A β may be attached to a solid support (for example, a test tube, bead, column, or microtiter dish), and fluorescent A β added, either before or in conjunction with a test modulatory compound. Aggregation is then monitored in response to the compound. In this assay, the extent of aggregation is indicated by the amount of fluorescent label associated with the solid support following appropriate washing. In both of these exemplary approaches, a negative control is preferably included for comparison purposes, in which no candidate compound is added.

In general, candidate modulatory compounds may be identified from large libraries of natural product or synthetic (or semi-synthetic) extracts or chemical libraries according to methods known in the art. Those skilled in the field of drug discovery and development will understand that the precise source of test extracts or compounds is not critical to the screening procedure(s) of the invention. Accordingly, virtually any number of chemical extracts or compounds can be screened using the exemplary methods described herein.

-29-

Examples of such extracts or compounds include, but are not limited to, plant-, fungal-, prokaryotic- or animal-based extracts, fermentation broths, and synthetic compounds, as well as modification of existing compounds.

Numerous methods are also available for generating random or directed
5 synthesis (e.g., semi-synthesis or total synthesis) of any number of chemical compounds, including, but not limited to, saccharide-, lipid-, peptide-, and nucleic acid-based compounds. Synthetic compound libraries are commercially available from Brandon Associates (Merrimack, NH) and Aldrich Chemical (Milwaukee, WI). Alternatively, libraries of natural
10 compounds in the form of bacterial, fungal, plant, and animal extracts are commercially available from a number of sources, including Biotics (Sussex, UK), Xenova (Slough, UK), Harbor Branch Oceanographics Institute (Ft. Pierce, FL), and PharmaMar, U.S.A. (Cambridge, MA). In addition, natural and synthetically produced libraries are produced, if desired, according to methods
15 known in the art, e.g., by standard extraction and fractionation methods. Furthermore, if desired, any library or compound is readily modified using standard chemical, physical, or biochemical methods.

Compounds identified as being capable of inhibiting A β aggregation are useful as therapeutics, or for the design of therapeutics, for Alzheimer's
20 disease. If desired, such compounds may be further tested for efficacy in Alzheimer's animal models.

What is claimed is:

-30-

Claims

1. A composition comprising an aggregating amyloid A β peptide to which is covalently bonded a fluorescent label.
2. The composition of claim 1, wherein said fluorescent label is covalently bonded to a cysteine amino acid.
3. The composition of claim 2, wherein said cysteine amino acid replaces an amino acid in a wild type A β peptide.
4. The composition of claim 3, wherein said cysteine amino acid replaces an internal amino acid.
5. The composition of claim 3, wherein said wild type amyloid A β peptide is a human wild type A β peptide.
6. The composition of claim 1, wherein said wild type amyloid A β peptide has the amino acid sequence of SEQ ID NO: 1.
7. The composition of claim 1, wherein said amyloid A β peptide has the amino acid sequence of SEQ ID NO: 2.
8. The composition of claim 3, wherein said cysteine amino acid replaces a hydrophobic amino acid.
9. The composition of claim 3, wherein said cysteine replaces a

-31-

phenylalanine amino acid at position 4 of SEQ ID NO: 1 or SEQ ID NO: 2.

10. The composition of claim 2, wherein said cysteine replaces an aspartic acid amino acid at position 7 of SEQ ID NO: 1 or SEQ ID NO: 2.

5 11. The composition of claim 2, wherein said cysteine replaces a glycine amino acid at position 25 of SEQ ID NO: 1 or SEQ ID NO: 2.

12. The composition of claim 2, wherein said cysteine replaces a leucine amino acid at position 34 of SEQ ID NO: 1 or SEQ ID NO: 2.

10 13. The composition of claim 1, wherein said fluorescent label is a thiol-reactive fluorescent dye.

14. The composition of claim 13, wherein said fluorescent label is chosen from 1,5-IEDANS or fluorescein.

15 15. The composition of claim 1, wherein said fluorescent label is chosen from Bodipy, FTC, Texas Red, phycoerythrin, rhodamine, carboxytetramethylrhodamine, DAPI, an indopyras dye, Cascade Blue, Oregon Green, eosin, erythrosin, pyridyloxazole, benzoxadiazole, aminonaphthalene, pyrene, maleimide, a coumarin, NBD, Lucifer Yellow, propidium iodide, a porphyrin, CY³, CY⁵, CY⁹, a lanthanide cryptate, a lanthanide chelate, or a derivative or analog thereof.

20 16. A method for generating an aggregating amyloid A β peptide, said method comprising:

-32-

(a) generating an amyloid A β peptide comprising a cysteine amino acid substitution;

(b) covalently bonding a fluorescent label to said peptide at said cysteine amino acid; and

5 (c) determining whether said peptide is capable of aggregating with another A β peptide.

17. The method of claim 16, wherein said cysteine substitution occurs at an internal amino acid.

18. An aggregating A β peptide produced by the method of claim 16.

10 19. A method for detecting or monitoring an amyloid aggregate in a sample, said method comprising

(a) contacting said sample with an aggregating amyloid A β peptide to which is covalently bonded a fluorescent label; and

15 (b) detecting said fluorescent label in association with said sample as an indication of an amyloid aggregate.

20. The method of claim 19, wherein said fluorescent label is covalently bonded to a cysteine amino acid.

21. The method of claim 19, wherein said method is carried out to diagnose Alzheimer's disease or a predisposition thereto.

20 22. The method of claim 19, wherein said cysteine amino acid replaces an amino acid in a wild type A β peptide.

-33-

23. The method of claim 19, wherein said cysteine amino acid replaces a hydrophobic amino acid.

24. The method of claim 19, wherein said cysteine amino acid replaces an internal amino acid in a wild type amyloid A β peptide.

5 25. The method of claim 19, wherein said aggregating A β peptide comprises a cysteine amino acid covalently bonded to a fluorescent label at any of amino acid positions 4, 7, 25, or 34 of SEQ ID NO: 1 or SEQ ID NO: 2.

26. The method of claim 19, wherein said fluorescent label is a thiol-reactive fluorescent dye.

10 27. The method of claim 19, wherein said fluorescent label is chosen from 1,5-IEDANS or fluorescein.

28. The method of claim 19, wherein said fluorescent label is chosen from Bodipy, FTC, Texas Red, phycoerythrin, rhodamine, carboxytetramethylrhodamine, DAPI, an indopyras dye, Cascade Blue, Oregon
15 Green, eosin, erythrosin, pyridyloxazole, benzoxadiazole, aminonaphthalene, pyrene, maleimide, a coumarin, NBD, Lucifer Yellow, propidium iodide, a porphyrin, CY³, CY⁵, CY⁹, a lanthanide cryptate, a lanthanide chelate, or a derivative or analog thereof.

29. A method for identifying a compound capable of affecting the
20 aggregation of A β amyloid peptide, said method comprising
(a) providing a sample of A β amyloid peptide;

-34-

(b) contacting said sample with (i) an aggregating amyloid A β peptide to which is covalently bonded a fluorescent label; and (ii) a candidate compound; and

5 (c) measuring association of said fluorescent label with said sample, a change in the level of fluorescent label found in association with said sample relative to a control sample lacking said candidate compound being an indication that said compound is capable of affecting A β amyloid peptide aggregation.

10 30. The method of claim 29, wherein said fluorescent label is covalently bonded to a cysteine amino acid.

31. The method of claim 29, wherein said sample comprises unlabeled A β amyloid peptide bound to a solid support and said aggregation is measured by association of said fluorescent label with said solid support.

15 32. A method for identifying a compound capable of affecting the aggregation of A β amyloid peptide, said method comprising

(a) providing a sample of an aggregating amyloid A β peptide to which is covalently bonded a fluorescent label;

(b) contacting said sample with a candidate compound; and

20 (c) measuring the ability of said peptide to aggregate, a change in the amount of aggregated peptide in the presence of said candidate compound relative to a sample lacking said compound being an indication that said compound is capable of affecting A β amyloid peptide aggregation.

33. The method of claim 32, wherein said fluorescent label is

-35-

covalently bonded to a cysteine amino acid.

34. The method of claim 29 or 32, wherein said compound inhibits A β amyloid peptide aggregation.

35. The method of claim 30 or 33, wherein said cysteine amino acid
5 replaces an internal amino acid in a wild type amyloid A β peptide.

36. The method of claim 29 or 32, wherein aggregation is measured by centrifugation, gel filtration, or fluorescence resonance energy transfer (FRET) analysis.

37. The method of claim 30 or 33, wherein said aggregating A β
10 peptide comprises a cysteine amino acid covalently bonded to a fluorescent label at any of amino acid positions 4, 7, 25, or 34 of SEQ ID NO: 1 or SEQ ID NO: 2.

38. The method of claim 29 or 32, wherein said fluorescent label is a thiol-reactive fluorescent dye.

1/10




Fig. 1

2/10




Fig. 2A

3/10




Fig. 2B

4/10




Fig. 3

5/10




Fig. 4A

6/10




Fig. 4B




Fig. 5A




Fig. 5B

8/10






Fig. 5C






Fig. 6C




Fig. 6D

SEQUENCE LISTING

<110> The Regents of University of California

<120> FLUORESCENT AMYLOID ABETA PEPTIDES AND
USES THEREOF

<130> 50016/002WO2

<140> NOT YET KNOWN

<141> 1998-08-13

<150> 60/055,660

<151> 1997-08-14

<160> 2

<170> FastSEQ for Windows Version 3.0

<210> 1

<211> 40

<212> PRT

<213> Homo sapiens

<400> 1

| | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Asp | Ala | Glu | Phe | Arg | His | Asp | Ser | Gly | Tyr | Glu | Val | His | His | Gln | Lys |
| 1 | | | | 5 | | | | 10 | | | | | | 15 | |
| Leu | Val | Phe | Phe | Ala | Glu | Asp | Val | Gly | Ser | Asn | Lys | Gly | Ala | Ile | Ile |
| | | 20 | | | | | | 25 | | | | | 30 | | |
| Gly | Leu | Met | Val | Gly | Gly | Val | Val | | | | | | | | |
| | | 35 | | | | | 40 | | | | | | | | |

<210> 2

<211> 42

<212> PRT

<213> Homo sapiens

<400> 2

| | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Asp | Ala | Glu | Phe | Arg | His | Asp | Ser | Gly | Tyr | Glu | Val | His | His | Gln | Lys |
| 1 | | | | 5 | | | | 10 | | | | | | 15 | |
| Leu | Val | Phe | Phe | Ala | Glu | Asp | Val | Gly | Ser | Asn | Lys | Gly | Ala | Ile | Ile |
| | | 20 | | | | | | 25 | | | | | 30 | | |
| Gly | Leu | Met | Val | Gly | Gly | Val | Val | Ile | Ala | | | | | | |
| | | 35 | | | | | 40 | | | | | | | | |

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US98/16809

| A. CLASSIFICATION OF SUBJECT MATTER IPC(6) :A61K 38/00; C07K 1/00; G01N 33/48, 33/566 US CL :530/300, 333, 402, 802; 436/63, 501 According to International Patent Classification (IPC) or to both national classification and IPC | | |
|---|--|---|
| B. FIELDS SEARCHED Minimum documentation searched (classification system followed by classification symbols) U.S. : 530/300, 333, 402, 802; 436/63, 501 Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) STN, MEDLINE, EMBASE, SCISEARCH, BIOSIS, APS | | |
| C. DOCUMENTS CONSIDERED TO BE RELEVANT | | |
| Category* | Citation of document, with indication, where appropriate, of the relevant passages | Relevant to claim No. |
| X ---, P Y | US 5,721,106 A (MAGGIO et al) 24 February 1998, see entire reference. | 1-2, 6-7, 13-15, 19-21, 25-30, 32- 34, 37-38 ----- 1-38 |
| X --- Y | US 5,434,050 A (MAGGIO et al) 18 July 1995, see entire reference. | 1-2, 13-15, 19-21, 26-30, 32-34, 38 ----- 1-38 |
| Y, P | US 5,786,328 A (DENNIS et al) 28 July 1998, see entire reference. | 1-12, 16-25, 29- 38 |
| <input checked="" type="checkbox"/> Further documents are listed in the continuation of Box C. <input type="checkbox"/> See patent family annex. | | |
| * Special categories of cited documents: *A* document defining the general state of the art which is not considered to be of particular relevance *B* earlier document published on or after the international filing date *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) *O* document referring to an oral disclosure, use, exhibition or other means *P* document published prior to the international filing date but later than the priority date claimed *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art *A* document member of the same patent family | | |
| Date of the actual completion of the international search 28 OCTOBER 1998 | | Date of mailing of the international search report 29 DEC 1998 |
| Name and mailing address of the ISA/US Commissioner of Patents and Trademarks Box PCT Washington, D.C. 20231 Facsimile No. (703) 305-3230 | | Authorized officer JOHN WEATHERSPOON Telephone No. (703) 308-0196 |

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US98/16809

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

| Category* | Citation of document, with indication, where appropriate, of the relevant passages | Relevant to claim No. |
|-----------|--|-----------------------|
| Y,P | US 5,780,265 A (DENNIS et al) 14 July 1998, see entire reference. | 1-12, 16-25, 29-38. |
| A | US 5,506,097 A (POTTER et al) 09 April 1996, see entire reference. | 1-38 |
| --- | | ----- |
| Y | | 5-12, 19-25, 37 |